ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
|Articles|April 12, 2023
Forecyte Bio Opens New GMP Facility in Shanghai
Author(s)Alivia Leon
Forecyte Bio has opened a new GMP facility in Shanghai just two months after its sister site in the United States.
Advertisement
Forecyte Bio held an opening ceremony on March 31, 2023, for its new cell and gene therapy good manufacturing practice (GMP) facility in Shanghai, China, following the successful opening of its United States facility in January 2023. The new Shanghai facility totals 140,000 ft2 with a total investment of nearly $40 million. It offers multiple GMP production lines for plasmids, viral vectors, and cell therapies.
The dual sites in the US and China offer advantages to cell and gene therapy (CGT) companies, as both facilities offer high-quality production capacities and an executive team experienced in CGT chemistry, manufacturing, and controls manufacturing. Forcyte Bio’s goal is to help its customers accelerate their product development process from R&D to clinic and to market. The company also enables CGT products to be manufactured and filed in multiple nations.
"The CGT industry has entered a stage of rapid development,” said Yingke He, founder and CEO of Forecyte Bio, during the opening ceremony. “With the opening of the Shanghai production and R&D center, the manufacturing capacity of Forecyte Bio in China and the United States are ready to serve its customers from US, China, and around the globe. Thanks to the trust and support from our landlord, our customers, and investors, and mostly our hardworking employees, we have been able to reach today's achievement in such a short time."
Source:
Advertisement
Related to this article
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5